$REGN REGENERON PHARMACEUTICALS, INC. Insider Trading Week 25/2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in REGENERON PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in REGENERON PHARMACEUTICALS, INC. in week 25/2017.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | Aberman Michael S | SVP Strategy Invest ... | Option Exercise | M | 30.63 | 4,500 | 137,835 | 3,000 | |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | Aberman Michael S | SVP Strategy Invest ... | Sell | S | 541.00 | 100 | 54,100 | 4,693 | 4.8 K to 4.7 K (-2.09 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | Aberman Michael S | SVP Strategy Invest ... | Sell | S | 538.30 | 100 | 53,830 | 4,793 | 4.9 K to 4.8 K (-2.04 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | Aberman Michael S | SVP Strategy Invest ... | Sell | S | 537.50 | 100 | 53,750 | 4,893 | 5 K to 4.9 K (-2.00 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | Aberman Michael S | SVP Strategy Invest ... | Sell | S | 536.52 | 400 | 214,608 | 4,993 | 5.4 K to 5 K (-7.42 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | Aberman Michael S | SVP Strategy Invest ... | Sell | S | 534.51 | 200 | 106,902 | 5,393 | 5.6 K to 5.4 K (-3.58 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | Aberman Michael S | SVP Strategy Invest ... | Sell | S | 533.48 | 200 | 106,696 | 5,593 | 5.8 K to 5.6 K (-3.45 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | Aberman Michael S | SVP Strategy Invest ... | Sell | S | 532.27 | 200 | 106,454 | 5,793 | 6 K to 5.8 K (-3.34 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | Aberman Michael S | SVP Strategy Invest ... | Sell | S | 531.51 | 274 | 145,634 | 5,993 | 6.3 K to 6 K (-4.37 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | Aberman Michael S | SVP Strategy Invest ... | Sell | S | 530.66 | 100 | 53,066 | 6,267 | 6.4 K to 6.3 K (-1.57 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | Aberman Michael S | SVP Strategy Invest ... | Sell | S | 529.61 | 100 | 52,961 | 6,367 | 6.5 K to 6.4 K (-1.55 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | Aberman Michael S | SVP Strategy Invest ... | Sell | S | 526.02 | 100 | 52,602 | 6,467 | 6.6 K to 6.5 K (-1.52 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | Aberman Michael S | SVP Strategy Invest ... | Sell | S | 525.21 | 395 | 207,458 | 6,567 | 7 K to 6.6 K (-5.67 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | Aberman Michael S | SVP Strategy Invest ... | Payment of Exercise | F | 510.02 | 1,961 | 1,000,149 | 6,962 | 8.9 K to 7 K (-21.98 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | Aberman Michael S | SVP Strategy Invest ... | Payment of Exercise | F | 510.02 | 270 | 137,705 | 8,923 | 9.2 K to 8.9 K (-2.94 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | Aberman Michael S | SVP Strategy Invest ... | Buy | M | 30.63 | 4,500 | 137,835 | 9,193 | 4.7 K to 9.2 K (+95.89 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Option Exercise | M | 30.63 | 20,000 | 612,600 | 26,736 | |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 541.70 | 100 | 54,170 | 23,950 | 24.1 K to 24 K (-0.42 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 540.04 | 100 | 54,004 | 24,050 | 24.2 K to 24.1 K (-0.41 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 539.36 | 200 | 107,872 | 24,150 | 24.4 K to 24.2 K (-0.82 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 538.39 | 600 | 323,034 | 24,350 | 25 K to 24.4 K (-2.40 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 537.42 | 200 | 107,484 | 24,950 | 25.2 K to 25 K (-0.80 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 536.46 | 800 | 429,168 | 25,150 | 26 K to 25.2 K (-3.08 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 535.37 | 800 | 428,296 | 25,950 | 26.8 K to 26 K (-2.99 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 534.64 | 700 | 374,248 | 26,750 | 27.5 K to 26.8 K (-2.55 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 533.49 | 905 | 482,808 | 27,450 | 28.4 K to 27.5 K (-3.19 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 532.44 | 500 | 266,220 | 28,355 | 28.9 K to 28.4 K (-1.73 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 531.42 | 900 | 478,278 | 28,855 | 29.8 K to 28.9 K (-3.02 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 530.64 | 800 | 424,512 | 29,755 | 30.6 K to 29.8 K (-2.62 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 529.61 | 100 | 52,961 | 30,555 | 30.7 K to 30.6 K (-0.33 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 526.45 | 600 | 315,870 | 30,655 | 31.3 K to 30.7 K (-1.92 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 525.10 | 400 | 210,040 | 31,255 | 31.7 K to 31.3 K (-1.26 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 524.08 | 101 | 52,932 | 31,655 | 31.8 K to 31.7 K (-0.32 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 523.52 | 200 | 104,704 | 31,756 | 32 K to 31.8 K (-0.63 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 522.80 | 200 | 104,560 | 31,956 | 32.2 K to 32 K (-0.62 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Sell | S | 521.70 | 100 | 52,170 | 32,156 | 32.3 K to 32.2 K (-0.31 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Payment of Exercise | F | 510.02 | 10,493 | 5,351,640 | 32,256 | 42.7 K to 32.3 K (-24.55 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Payment of Exercise | F | 510.02 | 1,201 | 612,534 | 42,749 | 44 K to 42.7 K (-2.73 %) |
| Jun 23 2017 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Buy | M | 30.63 | 20,000 | 612,600 | 43,950 | 24 K to 44 K (+83.51 %) |
| Jun 21 2017 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Option Exercise | M | 273.67 | 1,000 | 273,670 | 6,500 | |
| Jun 21 2017 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 500.01 | 1,000 | 500,010 | 13,000 | 14 K to 13 K (-7.14 %) |
| Jun 21 2017 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Buy | M | 273.67 | 1,000 | 273,670 | 14,000 | 13 K to 14 K (+7.69 %) |
| Jun 21 2017 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Option Exercise | M | 177.82 | 3,000 | 533,460 | 3,000 | |
| Jun 21 2017 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Sell | S | 500.00 | 3,000 | 1,500,000 | 0 | 3 K to 0 (-100.00 %) |
| Jun 21 2017 | REGN | REGENERON PHARMACE ... | BROWN MICHAEL S | Director | Buy | M | 177.82 | 3,000 | 533,460 | 3,000 | 0 to 3 K |
| Jun 19 2017 | REGN | REGENERON PHARMACE ... | Terifay Robert J | EVP Commercial | Option Exercise | M | 52.03 | 48,750 | 2,536,463 | 30,579 | |
| Jun 19 2017 | REGN | REGENERON PHARMACE ... | Terifay Robert J | EVP Commercial | Sell | S | 468.19 | 21,147 | 9,900,814 | 23,293 | 44.4 K to 23.3 K (-47.59 %) |
| Jun 19 2017 | REGN | REGENERON PHARMACE ... | Terifay Robert J | EVP Commercial | Payment of Exercise | F | 468.69 | 22,192 | 10,401,168 | 44,440 | 66.6 K to 44.4 K (-33.31 %) |
| Jun 19 2017 | REGN | REGENERON PHARMACE ... | Terifay Robert J | EVP Commercial | Payment of Exercise | F | 468.69 | 5,411 | 2,536,082 | 66,632 | 72 K to 66.6 K (-7.51 %) |
| Jun 19 2017 | REGN | REGENERON PHARMACE ... | Terifay Robert J | EVP Commercial | Buy | M | 52.03 | 48,750 | 2,536,463 | 72,043 | 23.3 K to 72 K (+209.29 %) |